A carregar...
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate canc...
Na minha lista:
| Publicado no: | Cells |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6721701/ https://ncbi.nlm.nih.gov/pubmed/31404966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells8080860 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|